|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||281.64 - 281.64|
|52 Week Range||281.64 - 281.64|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||58.44|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, today announced the latest updates to its SediVue Dx® Urine Sediment Analyzer, Catalyst Dx® and Catalyst One® chemistry analyzers, and IDEXX Web PACS™ cloud-based diagnostic imaging software, expanding the capabilities of each platform. These updates are designed to provide diagnostic tools that enhance patient care and drive productivity for veterinary teams by removing key workflow constraints.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, today announced that it is launching a new rapid digital cytology service that digitally connects veterinarians to the largest global network of more than 100 veterinary clinical pathologists and enables them to receive cytology interpretations within 2 hours. Powered by a new in-clinic instrument and IDEXX's proprietary VetConnect® PLUS software, the service will be available 24 hours a day, 7 days a week, 365 days a year. IDEXX Digital Cytology™ will be available to IDEXX customers in North America by mid-February.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced organizational changes to its global Companion Animal Group ("CAG") business aligned with leveraging best practices and execution capabilities to support global market development and sustained double-digit revenue growth.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2019 fourth quarter and full-year financial results for Friday, January 31, 2020 before the market opens. The Company will host a conference call beginning at 8:30 a.m. ET on that day.
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
The charts of IDEXX Laboratories and Zoetis have weakened recently, and while the Westminster Dog Show is not for a few more months, it looks like these stocks could be going to the dogs. In this daily bar chart of IDXX, below, we can see that prices traded sideways since June with buyers showing up around $260 until today.
Fido and Fluffy have health concerns, too, and animal health companies like Zoetis and Idexx Laboratories are in hot pursuit of the rapidly developing pet health market.
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
This is the second of two stories that Investopedia is devoting to a report from Goldman Sachs recommending stocks with longterm stable profit growth.
Shares of medical stocks Idexx Laboratories and Masimo approached breakouts Friday as Wall Street enjoyed a third day of gains. Both stocks are now in the process of forming flat bases.
IDEXX Laboratories and Zoetis Inc. appear ready to trade higher, offering stable opportunities as the dog-eat-dog trade war lingers on.
For his Executive Decision segment of "Mad Money" Wednesday our own Jim Cramer sat down with Jonathan Ayers, chairman, president and CEO of Idexx Laboratories Inc. IDXX, an animal health company. For those pets who do see their vet, however, diagnostics from Idexx are becoming an integral part of their care. Ayers said Idexx continues to innovate, which helps it see strong organic growth and increased operating margins.
"[Millennials] are more likely to go to the vet more frequently and more willing to listen to an advanced standard of care," CEO Jonathan Ayers says. About 42% of millennials think their pets have special health needs — more than double the percentage of the baby boomer generation, he said. Idexx Laboratories IDXX has room to grow in providing preventative care for pets, CEO Jonathan Ayers told CNBC Wednesday.
Chairman, President & CEO of Idexx Laboratories Inc (NASDAQ:IDXX) Jonathan W Ayers sold 28,000 shares of IDXX on 05/03/2019 at an average price of $249.02 a share.
On a per-share basis, the Westbrook, Maine-based company said it had net income of $1.17. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...